gyre therapeutics inc - GYRE

GYRE

Close Chg Chg %
4.39 0.12 2.73%

Open Market

4.51

+0.12 (2.73%)

Volume: 112.12K

Last Updated:

Nov 17, 2026, 3:07 PM EDT

Company Overview: gyre therapeutics inc - GYRE

GYRE Key Data

Open

$4.39

Day Range

4.32 - 4.56

52 Week Range

4.00 - 9.14

Market Cap

$497.03M

Shares Outstanding

115.32M

Public Float

25.73M

Beta

2.54

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.27

Yield

0.00%

Dividend

$0.24

EX-DIVIDEND DATE

Jan 13, 2023

SHORT INTEREST

N/A

AVERAGE VOLUME

222.69K

 

GYRE Performance

1 Week
 
1.86%
 
1 Month
 
-27.80%
 
3 Months
 
-34.28%
 
1 Year
 
-45.06%
 
5 Years
 
-77.66%
 

GYRE Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 3
Full Ratings ➔

About gyre therapeutics inc - GYRE

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The firm operates two distinct segments: Gyre Pharmaceuticals and Gyre. The Gyre Pharmaceuticals segment extends three major commercial drug products including ETUARY, Etorel, and Contiva as well as several product candidates in preclinical and clinical development. The Gyre segment consists of the development and commercialization of Hydronidone for the treatment of metabolic dysfunction-associated steatohepatitis associated liver fibrosis. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.

GYRE At a Glance

Gyre Therapeutics, Inc.
12770 High Bluff Drive
San Diego, California 92130
Phone 1-619-949-3681 Revenue 116.59M
Industry Pharmaceuticals: Major Net Income 5.03M
Sector Health Technology 2025 Sales Growth 10.241%
Fiscal Year-end 12 / 2026 Employees 625
View SEC Filings

GYRE Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 313.778
Price to Sales Ratio 6.248
Price to Book Ratio 6.08
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 50.904
Enterprise Value to Sales 6.117
Total Debt to Enterprise Value 0.001

GYRE Efficiency

Revenue/Employee 186,540.80
Income Per Employee 8,043.20
Receivables Turnover 3.156
Total Asset Turnover 0.80

GYRE Liquidity

Current Ratio 5.598
Quick Ratio 5.042
Cash Ratio 2.867

GYRE Profitability

Gross Margin 95.355
Operating Margin 9.856
Pretax Margin 12.382
Net Margin 4.312
Return on Assets 3.449
Return on Equity 5.937
Return on Total Capital 4.699
Return on Invested Capital 5.895

GYRE Capital Structure

Total Debt to Total Equity 0.886
Total Debt to Total Capital 0.878
Total Debt to Total Assets 0.565
Long-Term Debt to Equity 0.286
Long-Term Debt to Total Capital 0.283
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Gyre Therapeutics Inc - GYRE

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
794.00K 113.45M 105.76M 116.59M
Sales Growth
-89.18% +14,188.41% -6.78% +10.24%
Cost of Goods Sold (COGS) incl D&A
1.03M 4.64M 3.88M 5.42M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
230.00K 1.11M 1.59M 2.52M
Depreciation
230.00K 1.04M 1.55M 1.94M
Amortization of Intangibles
- 74.00K 38.00K 576.00K
COGS Growth
-86.60% +350.97% -16.22% +39.44%
Gross Income
(234.00K) 108.81M 101.87M 111.17M
Gross Income Growth
+29.52% +46,601.71% -6.38% +9.13%
Gross Profit Margin
-29.47% +95.91% +96.33% +95.35%
2022 2023 2024 2025 5-year trend
SG&A Expense
29.16M 89.60M 85.64M 99.68M
Research & Development
12.20M 13.78M 12.02M 13.70M
Other SG&A
16.96M 75.82M 73.62M 85.98M
SGA Growth
-65.03% +207.25% -4.42% +16.39%
Other Operating Expense
- - - -
-
Unusual Expense
36.22M 95.06M (7.17M) (2.71M)
EBIT after Unusual Expense
(65.62M) (75.85M) 23.40M 14.20M
Non Operating Income/Expense
57.72M (1.11M) (178.00K) 238.00K
Non-Operating Interest Income
537.00K 1.04M 1.55M 1.75M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(7.89M) (76.97M) 23.22M 14.44M
Pretax Income Growth
+91.02% -874.98% +130.17% -37.82%
Pretax Margin
-994.21% -67.84% +21.95% +12.38%
Income Tax
348.00K 8.52M 5.32M 4.56M
Income Tax - Current - Domestic
348.00K 6.00K 2.00K 2.00K
Income Tax - Current - Foreign
- 9.34M 6.32M 5.66M
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- (834.00K) (1.00M) (1.11M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(8.24M) (85.48M) 17.90M 9.88M
Minority Interest Expense
- 7.45M 5.81M 4.85M
Net Income
(8.24M) (92.93M) 12.09M 5.03M
Net Income Growth
+90.63% -1,027.55% +113.00% -58.40%
Net Margin Growth
-1,038.04% -81.92% +11.43% +4.31%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(8.24M) (92.93M) 12.09M 5.03M
Preferred Dividends
- - - -
-
Net Income Available to Common
(8.24M) (92.93M) 12.09M 5.03M
EPS (Basic)
-3.9191 -1.4117 0.142 0.0563
EPS (Basic) Growth
+90.90% +63.98% +110.06% -60.35%
Basic Shares Outstanding
2.10M 65.83M 85.09M 89.34M
EPS (Diluted)
-3.9191 -1.4117 0.0481 0.0225
EPS (Diluted) Growth
+90.90% +63.98% +103.41% -53.22%
Diluted Shares Outstanding
2.10M 65.83M 102.29M 103.18M
EBITDA
(29.17M) 20.33M 17.82M 14.01M
EBITDA Growth
+65.04% +169.69% -12.35% -21.36%
EBITDA Margin
-3,673.30% +17.92% +16.85% +12.02%

Snapshot

Average Recommendation BUY Average Target Price 18.667
Number of Ratings 3 Current Quarters Estimate -0.07
FY Report Date 12 / 2026 Current Year's Estimate -0.293
Last Quarter’s Earnings -0.04 Median PE on CY Estimate N/A
Year Ago Earnings 0.02 Next Fiscal Year Estimate -0.33
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 3 1 3 1
Mean Estimate -0.07 -0.15 -0.29 -0.33
High Estimates -0.01 -0.15 -0.17 -0.33
Low Estimate -0.11 -0.15 -0.37 -0.33
Coefficient of Variance -75.59 N/A -36.77 N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 3
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Gyre Therapeutics Inc - GYRE

Date Name Shares Transaction Value
May 21, 2026 Weiguo Ye Chief Operating Officer 700,200 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $0.75 per share 525,150.00
May 21, 2026 Weiguo Ye Chief Operating Officer 700,000 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.62 per share 4,634,000.00
May 21, 2026 Weiguo Ye Chief Operating Officer 709,120 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $0.75 per share 531,840.00
May 21, 2026 Weiguo Ye Chief Operating Officer 700,000 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.37 per share 4,459,000.00
May 21, 2026 Weiguo Ye Chief Operating Officer 936,235 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 21, 2026 Weiguo Ye Chief Operating Officer 927,115 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 21, 2026 Ping Zhang Director N/A Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 0.00
Jan 12, 2026 Ruo Yu Chen Chief Financial Officer 50,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Gyre Therapeutics Inc in the News